Overcoming cancer drug resistance

agreement-svg Q1 Report 2023

More about resistance

Cancer drug resistance

Pipeline

Pipeline

Financial reports

Financial Reports

Learn more about our unique first-in-class lead compound SCO-101

Presenting CEO Francois Martelet

A great place to work

For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatments

Read more